Absence of <i>EGFR</i> mutation in the kinase domain in common human cancers besides non‐small cell lung cancer

Abstract excerpt

The epidermal growth factor receptor (EGFR), a receptor protein tyrosine kinase, contributes to a number of processes in tumor survival and growth activity, thus making it a promising target for the cancer therapies.1 One of the agents that target the EGFR is the orally active EGFR tyrosine kinase inhibitor gefitinib (Iressa).2 The potential clinical benefits of gefitinib have been demonstrated in non-small cell...